Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Maintains $26 Price Target

Benzinga · 2d ago
Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $26 price target.